Intravenous Administration of Recombinant Ph α1β: Antinociceptive Properties and Morphine Tolerance Reversal in a Cancer-Associated Pain Model

This study aims to assess the antinociceptive effects resulting from intravenous administration of the recombinant form of Phα1β (r-Phα1β) in an experimental model of cancer-related pain in mice, tolerant or not to morphine. The model of cancer-induced pain was used to evaluate these effects, with the injection of B16F10 cells, followed by the administration of the r-Phα1β, and evaluation of the mechanical threshold by the von Frey test. Also, adverse effects were assessed using a score scale, the rotarod, and open field tests. Results indicate that the administration of r-Phα1β provoked antinociception in animals with cancer-induced mechanical hyperalgesia, with or without morphine tolerance. Previous administration of r-Phα1β was able to recover the analgesic activity of morphine in animals tolerant to this opioid. r-Phα1β was proved safe for these parameters, as no adverse effects related to motor and behavioral activity were observed following intravenous administration. This study suggests that the concomitant use of morphine and r-Phα1β could be a viable strategy for pain modulation in cancer patients.PMID:38614245 | DOI:10.1016/j.toxicon.2024.107717

Source: Toxicon - April 13, 2024 Category: Toxicology Authors: Mariana de Melo Cardoso Rahisa Scussel Jessica da Silva Abel Fernando Oriques Pereira Lidiane Anast ácio Cruz Franciane da Costa Constante Ellen De Pieri Helena Mendes Abelaira Juliano Ferreira Marcus Vin ícius Gomez Fl ávia K Rigo Ricardo Andrez Macha Source Type: research